Scan to Download ios&Android APP

Trade Basilea Pharma AG - BSLN CFD

37.95
4.86%
0.40
Low: 38
High: 40.1
Market Trading Hours* (UTC) Open now
Closes on Wednesday at 15:20

Mon - Fri: 07:00 - 15:20

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading Conditions
Long position overnight fee -0.0200%
Short position overnight fee -0.0244%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency CHF
Margin 20%
Stock exchange Switzerland
Commission on trade 0%

*Information provided by Capital.com

Basilea Pharmaceutica AG ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

Key Stats
Prev. Close* 40.15
Open* 40.1
Day's Range* 38 - 38
1-Year Change* -11.87%
Volume N/A
Average Vol. (3m) 0.77189
52 wk Range N/A
Market Cap 523.201
P/E Ratio N/A
Shares Outstanding 11848700
Revenue 148.122
EPS -0.61297
Dividend (Yield %) N/A
Beta 1.22322
Next Earnings Date Feb 13, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Aug 16, 2022 40.15 -2.50 -5.86% 42.65 42.90 40.05
Aug 15, 2022 43.05 -0.05 -0.12% 43.10 44.35 43.05
Aug 12, 2022 43.25 0.85 2.00% 42.40 43.80 42.40
Aug 11, 2022 42.80 1.50 3.63% 41.30 43.20 41.20
Aug 10, 2022 41.70 0.85 2.08% 40.85 41.75 40.05
Aug 9, 2022 40.95 -0.20 -0.49% 41.15 41.20 40.60
Aug 8, 2022 41.35 0.15 0.36% 41.20 41.50 40.80
Aug 5, 2022 41.35 0.10 0.24% 41.25 41.70 41.05
Aug 4, 2022 41.50 -1.05 -2.47% 42.55 42.55 41.40
Aug 3, 2022 42.60 0.30 0.71% 42.30 43.00 42.05
Aug 2, 2022 42.50 -0.95 -2.19% 43.45 43.50 42.15
Jul 29, 2022 43.75 -0.90 -2.02% 44.65 44.90 43.65
Jul 28, 2022 44.50 0.60 1.37% 43.90 44.70 43.15
Jul 27, 2022 43.80 1.95 4.66% 41.85 44.30 41.85
Jul 26, 2022 42.35 1.55 3.80% 40.80 43.00 40.55
Jul 25, 2022 40.95 1.15 2.89% 39.80 41.15 39.75
Jul 22, 2022 39.85 -0.15 -0.37% 40.00 40.70 39.75
Jul 21, 2022 40.25 -0.40 -0.98% 40.65 41.25 39.90
Jul 20, 2022 40.85 0.00 0.00% 40.85 41.35 40.45
Jul 19, 2022 41.05 1.30 3.27% 39.75 41.25 39.75

Basilea Pharma AG Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total revenue 65.984 101.521 132.555 134.381 127.629 148.122
Revenue 65.984 101.521 132.555 134.381 127.629 148.122
Cost of Revenue, Total 5.347 9.025 20.299 18.868 24.054 24.072
Gross Profit 60.637 92.496 112.256 115.513 103.575 124.05
Total Operating Expense 109.873 118.571 156.65 151.581 136.165 147.432
Selling/General/Admin. Expenses, Total 56.077 54.491 31.409 30.051 29.422 29.721
Research & Development 48.449 55.055 104.942 102.662 97.41 93.157
Operating Income -43.889 -17.05 -24.095 -17.2 -8.536 0.69
Interest Income (Expense), Net Non-Operating -6.379 -6.653 -6.528 -6.396 -7.485 -8.085
Other, Net -0.686 4.677 -0.537 1.214 1.354 0.601
Net Income Before Taxes -50.954 -19.026 -31.16 -22.382 -14.667 -6.794
Net Income After Taxes -51.287 -19.36 -31.352 -22.422 -14.722 -6.831
Net Income Before Extra. Items -51.287 -19.36 -31.352 -22.422 -14.722 -6.831
Net Income -51.287 -19.36 -31.352 -22.422 -14.722 -6.831
Income Available to Common Excl. Extra. Items -51.287 -19.36 -31.352 -22.422 -14.722 -6.831
Income Available to Common Incl. Extra. Items -51.287 -19.36 -31.352 -22.422 -14.722 -6.831
Diluted Net Income -51.287 -19.36 -31.352 -22.422 -14.722 -6.831
Diluted Weighted Average Shares 10.1211 10.8459 10.8379 10.7557 10.2815 11.682
Diluted EPS Excluding Extraordinary Items -5.06732 -1.78501 -2.89281 -2.08466 -1.43189 -0.58475
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -5.06732 -1.78501 -2.89281 -2.08466 -2.36256 -0.55793
Unusual Expense (Income) -14.721 0.482
Dec 2019 Jun 2020 Dec 2020 Jun 2021 Dec 2021
Total revenue 71.196 69.328 58.301 54.198 93.924
Revenue 71.196 69.328 58.301 54.198 93.924
Cost of Revenue, Total 9.498 13.085 10.969 13.525 10.547
Gross Profit 61.698 56.243 47.332 40.673 83.377
Total Operating Expense 75.202 56.514 79.651 69.808 77.624
Selling/General/Admin. Expenses, Total 13.881 14.449 14.973 14.339 15.382
Research & Development 51.823 43.939 53.471 41.689 51.468
Operating Income -4.006 12.814 -21.35 -15.61 16.3
Interest Income (Expense), Net Non-Operating -3.182 -3.135 -4.35 -4.075 -4.01
Other, Net 0.218 0.294 1.06 -0.192 0.793
Net Income Before Taxes -6.97 9.973 -24.64 -19.877 13.083
Net Income After Taxes -6.991 9.941 -24.663 -19.891 13.06
Net Income Before Extra. Items -6.991 9.941 -24.663 -19.891 13.06
Net Income -6.991 9.941 -24.663 -19.891 13.06
Income Available to Common Excl. Extra. Items -6.991 9.941 -24.663 -19.891 13.06
Income Available to Common Incl. Extra. Items -6.991 9.941 -24.663 -19.891 13.06
Diluted Net Income -6.991 9.941 -24.663 -19.891 13.06
Diluted Weighted Average Shares 10.7596 10.8592 9.79463 11.5653 11.7986
Diluted EPS Excluding Extraordinary Items -0.64975 0.91545 -2.51801 -1.71988 1.10691
Dividends per Share - Common Stock Primary Issue 0 0 0
Diluted Normalized EPS -0.64975 0.02004 -2.50222 -1.70555 1.12612
Unusual Expense (Income) -14.959 0.238 0.255 0.227
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total Current Assets 268.494 292.976 274.738 184.86 223.528 241.066
Cash and Short Term Investments 239.03 260.724 223.034 129.024 161.772 148.7
Cash 33.4 50.1 37.4 52.5 50.1 53.7
Cash & Equivalents 205.63 150.624 135.634 56.524 10.649 0
Short Term Investments 0 60 50 20 101.023 95
Total Receivables, Net 7.409 15.026 35.593 30.315 37.901 65.7
Accounts Receivable - Trade, Net 2.492 4.955 3.757 6.242 8.71
Total Inventory 14.931 15.32 14.411 18.569 21.192 22.783
Other Current Assets, Total 7.124 1.906 1.7 6.952 2.663 3.883
Total Assets 327.758 351.165 281.751 221.467 229.794 247.267
Property/Plant/Equipment, Total - Net 8.878 7.768 6.424 5.162 5.275 2.923
Property/Plant/Equipment, Total - Gross 45.178 45.1 45 44.2 29.348 17.505
Accumulated Depreciation, Total -36.3 -37.3 -38.6 -39 -24.1 -14.6
Intangibles, Net 0.232 0.326 0.372 0.372 0.672 0.632
Long Term Investments 50 50 0 30 0
Other Long Term Assets, Total 0.154 0.095 0.217 1.073 0.319 0.256
Total Current Liabilities 72.914 79.491 66.684 75.494 50.161 174.408
Accounts Payable 1.851 4.353 6.399 6.765 13.151 10.617
Accrued Expenses 14.9 19.6 26.7 29.3 29.052 33.453
Notes Payable/Short Term Debt 0 0 0 0 0 0
Other Current Liabilities, Total 56.163 55.538 33.585 39.429 7.958 6.833
Total Liabilities 362.758 392.605 348.438 314.427 331.84 305.874
Total Long Term Debt 195.466 196.224 196.982 197.74 239.668 94.544
Long Term Debt 195.466 196.224 196.982 197.74 239.668 94.544
Other Liabilities, Total 94.378 116.89 84.772 41.193 42.011 36.922
Total Equity -35 -41.44 -66.687 -92.96 -102.046 -58.607
Common Stock 11.812 11.872 11.879 11.882 11.922 12.992
Retained Earnings (Accumulated Deficit) -20.94 -33.108 -55.05 -74.324 -33.95 6.577
Treasury Stock - Common -1 -1 -7.235 -5.963 -52.766 -56.559
Other Equity, Total -24.872 -19.204 -16.281 -24.555 -27.252 -21.617
Total Liabilities & Shareholders’ Equity 327.758 351.165 281.751 221.467 229.794 247.267
Total Common Shares Outstanding 10.812 10.8717 10.7447 10.7739 10.8673 11.842
Note Receivable - Long Term 2.39
Current Port. of LT Debt/Capital Leases 123.505
Dec 2019 Jun 2020 Dec 2020 Jun 2021 Dec 2021
Total Current Assets 184.86 161.01 223.528 220.189 241.066
Cash and Short Term Investments 129.024 112.802 161.772 162.849 148.7
Cash & Equivalents 109.024 59.779 60.749 82.849 53.7
Short Term Investments 20 53.023 101.023 80 95
Total Receivables, Net 30.315 28.549 37.901 31.264 65.7
Accounts Receivable - Trade, Net 6.242 5.145 8.71 6.618
Total Inventory 18.569 13.184 21.192 20.94 22.783
Other Current Assets, Total 6.952 6.475 2.663 5.136 3.883
Total Assets 221.467 197.055 229.794 227.176 247.267
Property/Plant/Equipment, Total - Net 5.162 1.683 5.275 3.767 2.923
Property/Plant/Equipment, Total - Gross 44.2 25.5 29.348 20.772 17.505
Accumulated Depreciation, Total -39 -23.8 -24.1 -17 -14.6
Intangibles, Net 0.372 0.589 0.672 0.467 0.632
Long Term Investments 30 30 0
Other Long Term Assets, Total 1.073 3.773 0.319 0.363 0.256
Total Current Liabilities 75.494 37.823 50.161 37.707 174.408
Accounts Payable 6.765 1.723 13.151 5.378 10.617
Accrued Expenses 23.4 22.4 29.052 25.235 33.453
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 45.329 11.9 7.958 7.094 6.833
Total Liabilities 314.427 276.631 331.84 305.928 305.874
Total Long Term Debt 197.74 198.118 239.668 227.869 94.544
Long Term Debt 197.74 198.118 239.668 227.869 94.544
Other Liabilities, Total 41.193 40.69 42.011 40.352 36.922
Total Equity -92.96 -79.576 -102.046 -78.752 -58.607
Common Stock 11.882 11.92 11.922 12.931 12.992
Retained Earnings (Accumulated Deficit) -74.324 -60.48 -33.95 -10.401 6.577
Treasury Stock - Common -5.963 -6.875 -52.766 -56.309 -56.559
Other Equity, Total -24.555 -24.141 -27.252 -24.973 -21.617
Total Liabilities & Shareholders’ Equity 221.467 197.055 229.794 227.176 247.267
Total Common Shares Outstanding 10.7739 10.8008 10.8673 11.7932 11.842
Current Port. of LT Debt/Capital Leases 1.8 123.505
Note Receivable - Long Term 2.39 2.39
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Net income/Starting Line -51.287 -19.36 -31.352 -22.422 -14.722 -6.831
Cash From Operating Activities -75.003 19.014 -79.21 -63.836 -54.134 -32.02
Cash From Operating Activities 2.319 1.991 1.852 1.639 1.19 0.754
Non-Cash Items 8.796 5.374 7.009 3.806 -9.84 5.844
Changes in Working Capital -34.831 31.009 -56.719 -46.859 -30.762 -31.787
Cash From Investing Activities 1.211 -60.94 59.391 -0.404 -34.963 3.575
Capital Expenditures -0.431 -0.945 -0.609 -0.404 -2.265 -0.86
Other Investing Cash Flow Items, Total 1.642 -59.995 60 0 -32.698 4.435
Cash From Financing Activities 0.411 2.631 -5.986 1.309 45.067 16.64
Issuance (Retirement) of Stock, Net 0.411 2.631 -5.986 1.309 4.809 39.852
Issuance (Retirement) of Debt, Net 0 43.451 -23.212
Foreign Exchange Effects -0.653 0.989 -1.011 0.067 -0.758 0.501
Net Change in Cash -74.034 -38.306 -26.816 -62.864 -44.788 -11.304
Cash Taxes Paid 0.283 0.413 0.141 0.026 0.035
Cash Interest Paid 5.756 5.795 5.666 4.843 7.074
Financing Cash Flow Items -3.193
Dec 2019 Jun 2020 Dec 2020 Jun 2021 Dec 2021
Net income/Starting Line -22.422 9.941 -14.722 -19.891 -6.831
Cash From Operating Activities -63.836 -33.171 -54.134 -27.151 -32.02
Cash From Operating Activities 1.639 0.817 1.19 0.399 0.754
Non-Cash Items 3.806 -12.657 -9.84 2.705 5.844
Changes in Working Capital -46.859 -31.272 -30.762 -10.364 -31.787
Cash From Investing Activities -0.404 -16.231 -34.963 19.113 3.575
Capital Expenditures -0.404 -0.871 -2.265 -0.307 -0.86
Other Investing Cash Flow Items, Total 0 -15.36 -32.698 19.42 4.435
Cash From Financing Activities 1.309 1.097 45.067 26.195 16.64
Issuance (Retirement) of Stock, Net 1.309 1.097 4.809 38.82 39.852
Foreign Exchange Effects 0.067 -1.093 -0.758 0.249 0.501
Net Change in Cash -62.864 -49.398 -44.788 18.406 -11.304
Financing Cash Flow Items -3.193
Issuance (Retirement) of Debt, Net 43.451 -12.625 -23.212

Why choose Capital.com? Our numbers speak for themselves.

Capital.com Group
427000+

Traders

71000+

Active clients monthly

$46000000+

Monthly investing volume

$17000000+

Withdrawn each month

Basilea Company profile

About Basilea Pharmaceutica AG

Basilea Pharmaceutica AG is a Switzerland-based commercial-stage biopharmaceutical company. The Company operates in one segment, which is the discovery, development and commercialization of innovative pharmaceutical products to meet the needs of patients with cancer and infectious diseases. It launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections. Additionally It is conducting clinical studies with two targeted drug candidates for the treatment of a range of cancers and have a number of preclinical assets in both cancer and infectious diseases in its portfolio.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Basilea Pharmaceutica AG revenues increased 16% to SF148.1M. Net loss decreased 54% to SF6.8M. Revenues reflect Japan segment increase of 41% to SF56.5M, Republic of Ireland segment increase of 9% to SF62.1M. Lower net loss reflects Research & development expenses, net - B decrease of 4% to SF91.6M (expense), Stock-based Compensation in SGA decrease of 6% to SF1.7M (expense).

Industry: Biotechnology & Medical Research (NEC)

Grenzacherstrasse 487
BASEL
BASEL-STADT 4058
CH

Income statement

People Also Watch

US Natural Gas Spot

9.44 Price
-0.260% 1D Chg, %
Long position overnight fee -0.0007%
Short position overnight fee -0.0126%
Overnight fee time 21:00 (UTC)
Spread 0.005

Still looking for a broker you can trust?

Join the 427.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading